Top Ten most popular articles on Pharmafile.com this week
pharmafile | July 3, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | COVID-19, coronaviurs, top 10
Gilead features prominently in the news this week, as the US bought most of the world’s stock of the company’s drug remdesivir, which is one of the only drugs proven to treat COVID-19, while announcing it will charge $2,340 for a 5 day course of the treatment.
In other news, Pfizer has filed a lawsuit against the US government to allow it to directly help with the copayments of Medicare recipients for the company’s cardiovascular drugs while the National Institutes of Health had its funding cut from a research project into bat coronavirus, according its Director Dr Anthony Fauci.
1. NIH ordered to cancel coronavirus research funding by White House, Dr Fauci tells Congress
The National Institutes of Health had its funding cut from a research project into bat coronavirus, according its Director Dr Anthony Fauci.
The UK Government warned when relaxing lockdown measures on 23 June that it would not hesitate to lock down any region which began to show an uncontrolled rise in COVID-19 cases.
3. Vaxart announces its COVID-19 vaccine has been selected by US Operation Warp Speed programme
Vaxart has announced the selection of its lead vaccine candidate for COVID-19 by Operation Warp Speed, a program to find a vaccine for the US by the end of the year.
4. COVID-19 immunity may be more widespread than previously thought, new study suggests
Coronavirus immunity in the world’s population may be more widespread than initially thought, even in those who have tested negative for antibodies, a new study suggests.
5. Pfizer sues US for permission to help Medicare patients with rare heart conditions
Pfizer has filed a lawsuit against the US government to allow it to directly help with the copayments of Medicare recipients for the company’s cardiovascular drugs.
6. AstraZeneca continues to ramp up COVID-19 vaccine production with new CMO partnership
AstraZeneca has continued to build its manufacturing capacity to deliver its COVID-19 vaccine candidate, developed in partnership with the University of Oxford and currently being tested in human trials across a number of trials across the UK, with its latest partnership signed with Scottish firm Symbiosis Pharmaceutical Services.
7. US buys most of the world’s stock of COVID-19 drug remdesivir
The US has bought most of the world’s stock of the drug remdesivir which is one of the only drugs proven to treat COVID-19.
8. China’s COVID-19 vaccine candidate approved for military use
China’s military have received approval to use a new vaccine candidate for coronavirus after clinical trials proved it was safe and showed some efficacy.
The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, Abicipar pegol, as treatment for the eye condition known as neovascular age-related macular degeneration (nAMD).
10. Gilead facing criticism for charging $2,340 for remdesivir
Gilead has announced that it will charge $2,340 for a 5 day treatment course of remdesivir, a drug that has been proven to reduce the symptoms of COVID-19.
Conor Kavanagh
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
